A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if subjects on 2g AMG 223 will achieve 60% or
greater reduction in urinary phosphorus from baseline compared to subjects on 2g Renagel®.
Renagel®, Sevelamer HCl is currently the market leader for the treatment of hyperphosphatemia
in patients on dialysis.